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cited2As a NODAL pathway inhibitor, EBAF plays a critical role duringmammalian cardiac development. As recent tests
that have been conducted on gene-targeted mice indicate, its expression is frequently altered where cardiac de-
fects are present. We aimed to explore the EBAF expression pattern and molecular mechanism of EBAF gene for
VSD genesis. In this report, we show that the average expression of EBAF in the disease tissues of VSD patients
was lower than the expression in normal fetuses without VSD. Further study showed that the expression pattern
of EBAF was potentially involved in cardiomyocyte apoptosis by Annexin-V and RT-PCR assays. We also found
that abnormal activation of NODAL-PITX2C pathwaywas associatedwith down-regulation of EBAF. By luciferase
reporter assays, we ﬁnd that EBAF expression is mediated by transcriptional factors smad2 and cited2. In
addition, ChIP assays showed that histone acetyltransferase p300 is involved in the activation of EBAF
through inducing hyperacetylation of histone H4 at the EBAF promoter. Co-immunoprecipitation also indi-
cates that the expression of EBAF is regulated by a transcriptional complex including p300, smad2, and
cited2. This study revealed a novel regulator mechanism of EBAF, which may be a potential molecular target
for halting the onset of VSDs. They also indicate that smad2, cited2, and p300 may play important roles in
modulating the conﬁrmation of ventricular septal defects.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Congenital heart disease (CHD) is the clinical manifestation of
anomalies in the heart and great vessels; it is the leading cause of
non-infectious infant mortality, with an incidence about 6/1000 [1,2].
As the number of patients with CHD increases, the disease has become
a signiﬁcant part of the overall disease burden for which government
health agencies are responsible [3]. Ventricular septal defect (VSD) is
the most commonly recognized CHD [4]. VSDs take different forms;
around 70–80% take the form of a membranous ventricular septal
defect, about 20% take the formof a supracristal ventricular septal defect,
around 5% take the form of an atrioventricular canal defect, and fewer
than 5% of VSDs are muscular defects. VSD genesis is a multifactorial
and complex condition in which both genetic and environmental factors
play important roles. Although the embryology and physiology of VSDs
arewidely known, their etiology and pathogenesis are still not very clear.
Recent genetic studies have uncovered a large number of genes in
connection with familial and sporadic forms of CHD [5,6]. Manyal Research Institute for Family
hina. Tel.: +86 1062117712;
t.cn (X. Ma).
ights reserved.transcription factors have been described as regulators of cardiac-
speciﬁc gene expression [7,8]. For instance, CITED2 (a cAMP-responsive
element-binding protein [CBP]/p300-interacting transactivator with
ED-rich C-terminal domain) has been found to be essential for normal
development of the heart [9], as evidenced by the fact that mice lacking
Cited2 die in utero showing various cardiac malformations including
atrial and ventricular septal defects, and overriding aortas [10]. Smad2,
another transcriptional factor, has been found to have a detrimental ef-
fect on embryo development [11,12], but its role in cardiac development
has not been clearly clariﬁed.
EBAF, as a Nodal pathway inhibitor [13] has been found to lack
any expression [9,14] in Cited2-null embryos with cardiac
malformations. But the correlation between expression patterns of
EBAF and cardiac malformations genesis is still unclear. In this
paper, for the ﬁrst time, we show that the expression of EBAF is fre-
quently down-regulated in patients with supracristal ventricular
septal defects, membranous ventricular septal defects, and atrioven-
tricular canal type ventricular septal defects. We also show that the
down-regulation of the EBAF gene may be partially attributed to
the transcriptional modulators smad2 and cited2. Moreover, we
ﬁnd that histone acetyltransferase p300 is involved in the activation
of EBAF by inducing the hyperacetylation of histone H4 in the EBAF
promoter, indicating that histone acetylation may play an important
role in heart development.
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2.1. Tissue samples
Fetal myocardial tissue samples were obtained from Shengjing Hospi-
tal of China Medical University. Myocardial tissue samples from 16 VSD
and 16 normal fetuses at 22–28 weeks of gestationwere obtained during
surgery for pregnancy termination owing to trauma of the pregnant
women. The specimens were immediately frozen in liquid nitrogen and
then stored at −80 °C until analysis. The study project about roles of
gene transcriptional regulation in congenital heart genesis was reviewed
and the protocol was approved by the Ethics Committee of the National
Research Institute for Family Planning (Permit Number: 2012-7). In-
formed consentwas obtained fromeach pregnantwoman andher family.
The study protocol followed the principles of the Declaration of Helsinki.
2.2. Cell culture, transfection, and luciferase reporter assay
Human cardiac myocytes (HCM) were maintained in Dulbecco's
Modiﬁed Eagle's Medium supplemented with 10% fetal bovine serum,
100 mg/ml penicillin, and 100 mg/ml streptomycin in a humidiﬁed at-
mosphere containing 5% CO2 at 37 °C. Transient transfection HCM cells
were performed using the Lipofectamine 2000 (Invitrogen) procedures.
Transfected cells were assayed for luciferase reporter activity using a
Promega dual-luciferase reporter assay system, and the Renilla lucifer-
ase control plasmid pREP7-RLuc was co-transfected for normalization.
2.3. Apoptosis assay
Myocardial cells were exposed to deferoxamine mesylate (DFO,
8 mM; Sigma) for 72 h, which served as an established hypoxia
model system and induced cell apoptosis. Cells were harvested using
trypsin and incubated at room temperature for 5 min in the dark with
Annexin V-FITC and propidium iodide according to the instructions of
the kit (Roche, Germany). The ﬂuorescence of FITC and PI was analyzed
by ﬂow cytometry.
2.4. RNA isolation, reverse transcription and real-time PCR
RNA was extracted from the heart tissues using the TRIzol Reagent
(Invitrogen) according to the manufacturer's protocol. cDNA was syn-
thesized from 2 μg of RNA using a RNA PCR kit (TaKaRa, Dalian, China).
Real-time PCR was performed on an ABI Prism7000 Sequence Detection
System (Applied Biosystems), following the manufacturer's protocol,
with SYBR Green (TaKaRa, Osaka, Japan) used as a double-strandedFig. 1. Three-dimensional ultrasound images of fetal hearts. (A) A representative picture of 16 c
three times). The representative picture showed the size of the defect in the heart shown herew
have no VSDs were used as controls.DNA-speciﬁc ﬂuorescent dye. Primer sequences are reported in the
Supplementary material online.
2.5. Western blotting
Frozen heart tissues from patients and controls were lysed in buffer.
Total proteinwas applied to a 12% SDS-polyacrylamide gel. After electro-
phoresis, polyvinylidene ﬂuoride (PVDF)membranewas incubatedwith
anti-EBAF (Santa Cruz), anti-cited2 (Abcam), anti-β-actin (Sigma). The
signals were visualized by using the Chemiluminescent Substrate meth-
od with the SuperSignal West Pico kit provided by Pierce Co.
2.6. CoIP (co-immunoprecipitation) assay
Co-IP was performed in HCM cells as described previously [15]. Total
cell extracts from smad2-GFP transfected cells were pre-cleared with
40 μl protein A-agarose at 4 °C for 1 h. The supernatant was incubated
with the smad2 antibody (Cell Signaling Technology)with gentle shaking
for 4 °C followed by addition of 40 μl of protein A-agarose for another 3 h.
The beadswere resuspended in 100 μl of 2× loading buffer and boiled for
10 min. The proteins were separated on a 12% SDS-PAGE gel and then
transferred to polyvinylidene ﬂuoride membrane for Western blotting
detection with anti-cited2 (Abcam) or anti-p300 antibody (Santa Cruz).
2.7. Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out using a kit supplied by Upstate follow-
ing themanufacturer's protocol. Cellswere cross-linkedwith 2% formal-
dehyde for 10 min at 37 °C, and then lysed in SDS lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris, pH 8.1) with protease inhibitors. After
ultrasonication, DNA was immunoprecipitated with antibodies against
Ac-H3 (Upstate), Ac-H4 (Upstate), p300 (Santa Cruz), cited2 (Abcam)
and smad2 (Cell Signaling Technology). The precipitated chromatin
was analyzed by PCR and real time quantitative RCR following the
manufacturer's protocol. To calculate the relative abundance of a given
gene promoter present in an immunoprecipitate, the following formula
was used: Qgene = IPgene/input gene, to calibrate the variation be-
tween different samples. Primer sequences are reported in the Supple-
mentary material online. All the experiments were repeated three
times, and one of the representative results is shown in the text.
2.8. Plasmid constructs
A 600-bp fragment of EBAF enhancer including ASE (asymmetric en-
hancer) and a 1300-bp fragment of the PITX2C promoter was ampliﬁedases of VSDs, whichwere diagnosed using three-dimensional echocardiography (repeated
as 4.9 mm. (B) Fetuses that were revealed by the three-dimensional echocardiography to
Table 1
Classiﬁcation of ventricular septal defects for our study.
Phenotype of
tissue donors
Subtypes of the sample Sample no.
Ventricular septal
defect
Supracristal ventricular
septal defect
S144, S162
Membranous ventricular
septal defect
M73,M65,M96,M145,M142,M150,
M98, M194, M160, M195, M173,
M179, M183
Atrioventricular
ventricular septal defect
A181
Normal Null N66, N110, N147, N116, N146, N120,
N132,N01,N88,N89,N90,N91,N141,
N107, N108, N140
S: supracristal ventricular septal defect.
M: membranous ventricular septal defect.
A: atrioventricular ventricular septal defect.
N: normal.
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cloned into the KpnI and XhoI digested luciferase reporter construct
PLG3-basic vector, respectively. The open reading frames of smad2,
EBAF, nodal or cited2 were ampliﬁed by PCR from human cDNA and
inserted into the HindIII and XhoI digested GFP vector or pcDNA3-Flag
vector to create smad2-GFP, EBAF-GFP, nodal-GFP or Flag-Cited2 fusion
protein, respectively. The pcDNA3.1-p300 plasmid was provided by
Huang Baiqu (Institute of Genetics and Cytology, Northeast Normal Uni-
versity, China).
2.9. Statistical analysis
Student's t test was used to calculate the statistical signiﬁcance of the
experimental data. The signiﬁcance level was set as *p b 0.05; #p b 0.05;
**p b 0.01; ##p b 0.01. Error bars denote the standard deviations.Fig. 2.Down-regulation of EBAFwas associatedwith VSDs genesis. (A) Comparison of EBAF mR
by quantitative PCR. Normal represents the average expression of EBAF mRNA inmyocardial tis
samples from16 patients with VSDs (combined) is also shown. β-actin was used as the internal
tween the normal controls and the different subtypes of VSDs respectively.M-VSD, S-VSD, A-VS
and atrioventricular canal type defects, respectively. **p b 0.01 versus normal group. (C) EBAF
with different subtypes of VSDs compared with EBAF proteins in the 10 normal samples which
reference.3. Results
3.1. Clinical evaluation of ventricular septal defects
Patients underwent a three-dimensional echocardiography to diag-
nose whether their fetuses showed any indication of VSDs. As shown in
Fig. 1A, fetal ventricular septal defect size was 4.9 mm. The three-
dimensional echocardiography identiﬁed 16 VSD fetuses at 22–
28 weeks of gestation. The sizes of the defects of 16 VSDs ranged from
4.6–8 mmat 22–28 weeks of gestation. NoVSDswere found in the con-
trol group,whohad been identiﬁed during the three-dimensional echo-
cardiography diagnosis phase (Fig. 1B). Myocardial tissue samples were
obtained during surgery for pregnancy termination owing to trauma of
the pregnant women. The 16 cases of fetal VSD were conﬁrmed by au-
topsy after induced labor. As shown in Table 1, 13 cases were found to
be defects of the membranous septum, 2 were found to be supracristal
ventricular septal defects, and 1 was found to be an atrioventricular
canal type ventricular septal defect.
3.2. Down-regulation of EBAF in the heart tissues of patients with VSDs
We ﬁrst assessed the expression of EBAF in myocardial tissue sam-
ples from 32 patients (16 patients with different subtypes of VSDs and
16 normal fetuses without VSD) using quantitative RT-PCR. The average
expression of EBAF in the patients with VSDs was lower than the aver-
age value of EBAF expression in 16 normal fetuses without VSD
(Fig. 2A). Speciﬁcally,as shown in Fig. 2B, EBAF was frequently down-
regulated in membranous ventricular septal defects (one subtype of
VSD). Though the expression of EBAF was also down-regulated in
supracristal ventricular septal defects and atrioventricular ventricular
septal defect (another two subtypes of VSD) in our study (Fig. 2B), the
results should be further conﬁrmed by increasing the numbers of the
samples. As conﬁrmed by Western blotting, the level of EBAF proteinNA expression in 32 samples (16 samples with VSDs and 16 samples without), as revealed
sue samples from 16 normal fetuses. The average expression of EBAF in myocardial tissue
reference. **p b 0.01 versus normal group. (B) Comparison of EBAF mRNA expression be-
D representmembranous ventricular septal defects, supracristal ventricular septal defects,
proteins, as detected by Western blotting, were found to be lower in the 10 VSD patients
were selected from the 32 sample pairs mentioned above, β-actin was used as the internal
Fig. 3.Down-regulation of EBAFwas associatedwith cardiomyocyte apoptosis. (A) DFO-induced apoptosis in cardiomyocytes. UntreatedHCM cells (left panel) andHCM cells treatedwith
DFO at 8 mM for 72 h (right panel)were examined for apoptotic response by Annexin V-FITC assay. The lower left population of cells in each plot represents viable cells which excluded PI
and didn't bind Annexin V, the upper left population cells comprise necrotic cells, which did not exclude PI and were not stained with FITC-labeled Annexin V. The lower and upper right
populations correspond to early apoptotic and late apoptotic cells, respectively. The percentages of early and late apoptotic cells, non-apoptotic and necrotic cells are shown in the right
lower quadrant, right upper quadrant, left lower quadrant and left upper quadrant, respectively. (B) RT-PCR analysis of the mRNA expression of EBAF during DFO-induced
apoptosis. β-actin was used as the internal reference.
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subtypes of VSDs comparedwith the 10normal sampleswhichwere se-
lected from the 32 samples mentioned above (Fig. 2C). The resultsFig. 4. Cited2 participated in regulating the expression of EBAF gene. (A) Western blotting con
tissues. (B) Low expression of CITED2 is associatedwith down-regulation of EBAF inDFO-induc
activity of EBAF. HCM cells were transfected with EBAF reporter plasmid, together with cited2
was observed 30 h after transfection andwas normalized to the Renilla activity. The vector wasindicated that the expression of EBAF was, on average, down-
regulated in the disease tissues of VSD patients, and this may play a sig-
niﬁcant role in the development of human VSD.ﬁrmed that low expression of CITED2 was associated with low expression of EBAF in VSD
ed apoptosis in cardiomyocytes. (C) Transcriptional regulator cited2 elevated the promoter
expression plasmids; they were also lysed for luciferase reporter assay. Luciferase activity
used as a negative control. ∗p b 0.05; ∗∗p b 0.01 comparedwith the control group (n = 3).
Fig. 5. cited2 and smad2 function cooperatively in transcriptional activation of the EBAF gene. (A) Characterization of EBAF gene responsive regulatory sequences. ASE regulatory region
and sequence location of smad2 are shown in the sub-ﬁgure. In addition, the location of the EBAF promoter region for ChIP assay has been underlined for speciﬁcation in the sub-
ﬁgure. (B) Transcriptional regulators smad2 elevated the promoter activity of EBAF. HCM cells were transfected with EBAF reporter plasmid, together with smad2 expression
plasmids; they were also lysed for luciferase reporter assay. (C) cited2 and smad2 cooperatively up-regulated EBAF promoter activity. HCM cells were transfected with EBAF
reporter plasmid, together with smad2 and cited2 expression plasmids, and lysed for luciferase reporter assay. (D) smad2 or cited2 over-expression potentiated their binding
activities at the EBAF promoter. Samples were immunoprecipitated (IP) with smad2 or cited2 antibodies and ampliﬁed by PCR.
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We therefore aimed to identify the biological characteristics of the
EBAF gene in myocardial cells. The ﬂow cytometry analysis showed
DFO-induced apoptosis in cardiomyocytes (Fig. 3A). Then we assessed
the expression of EBAF by comparing control cells and DFO-treated
cells using quantitative RT-PCR. As shown in Fig. 3B, the average ex-
pression of EBAF in DFO-induced apoptotic cells was lower than the
EBAF expression in untreated cells. The results indicated that down-
regulation of EBAF was associated with cardiomyocyte apoptosis.
Thus, down-regulation of EBAF may be potentially involved in heart
malformations.
3.4. Cited2 played an important role in the expression regulation of EBAF
gene
To explore the molecular mechanism of EBAF under-expression in
VSD, we ﬁrst identiﬁed the EBAF regulator. Western blotting showedthat low expression of cited2 was associated with low expression of
EBAF in VSD tissues (Fig. 4A). Furthermore, we also ﬁnd that low ex-
pression of CITED2 is associated with down-regulation of EBAF in
cardiomyocyte apoptosis (Fig. 4B). In addition, luciferase reporter as-
says showed that cited2 over-expression up-regulated EBAF promoter
activity (Fig. 4C). Data above showed that cited2 participated in regulat-
ing the expression of EBAF gene.
3.5. Smad2 cooperates with cited2 to activate the EBAF promoters
The promoter fragments of the EBAF gene contain several GCAT or
GTCTmotifs, which are potential BR-Smad binding sites [16]. Moreover,
through sequence analysis and reference basis, we detected several pu-
tative binding sites for the transcription factor smad2 in the ASE region
of the EBAF promoter (Fig. 5A) [20,21]. Therefore, these data prompted
us to examine the possibility of the cooperation of smad2with cited2 on
upregulation of EBAF gene. Firstly, luciferase reporter assays showed
that smad2 and cited2 overexpression increased EBAF promoter activity
Fig. 6. p300 over-expression up-regulates the expression of EBAF by enhancing the acety-
lation levels of histone H4 at the EBAF promoter. (A) p300 up-regulated EBAF promoter
activity by luciferase reporter assay. (B) Over-expression of p300 increased the enrich-
ment of p300 at the EBAF promoter. HCM cells transfected with p300 expression plasmid
were subjected to ChIP assays. (C) The acetylation levels of histones H4 were assessed
using ChIP assays. HCM cells were transfected with p300 expression plasmid and
harvested for ChIP assays. Samples were immunoprecipitated using anti-Ac-H3 or Ac-H4
antibodies, and the precipitated DNAs were ampliﬁed using PCR.
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the promoter activity of the EBAF gene was up-regulated signiﬁcantly
higher upon the co-expression of cited2 and smad2 than transfection
with smad2 and cited2, respectively (Fig. 5C). Furthermore, chromatin
immunoprecipitation (ChIP) assays showed that smad2 was able to
bind to the EBAF promoter, and that the over-expression of smad2 in-
creased its enrichment at the EBAF promoter (Fig. 5D, left). Likewise,
cited2 was also present at the EBAF promoter (Fig. 5D, right). This indi-
cates that both smad2 and cited2 participate in regulating the expres-
sion of EBAF.3.6. The role of p300 in inducing histone H4 hyperacetylation at the EBAF
promoter
P300 has a domainwith intrinsic histone acetyltransferase (HAT) ac-
tivity, and it plays an important role in chromatin remodeling [17]. p300
was reported to interact physically with cited2. We examined whether
p300 regulated the expression of EBAF. Luciferase reporter assays
showed that the promoter activity of EBAF was up-regulated by trans-
fection with p300 expression plasmid (Fig. 6A). ChIP assays showedFig. 7. smad2, cited2, and p300 coordinate to up-regulate the expression of EBAF. (A) cited2
transfectedwith EBAF reporter plasmid, together with smad2, p300, and cited2 expression plas
in the same complex by Co-IP assays. HCM cells transfected with the smad2-GFP expression pl
Western blotting with anti-p300 or anti-cited2 antibody.that over-expression of p300 increased the enrichment of p300 at the
EBAF promoter (Fig. 6B and Supplemental Fig. S1A). Furthermore, H4
acetylation levels at the EBAF promoter were also found to increase
when there was p300 over-expression.Meanwhile, there was no signif-
icant increase in the H3 acetylation levels (Fig. 6C, Supplemental
Fig. S1B and C). These results clearly indicate that the presence of
p300 at the EBAF promoter enhances the acetylation levels of histone
H4 at the EBAF promoter.
3.7. p300, smad2, and cited2 in the same transcriptional complex
We next examined whether smad2, cited2, and p300 cooperated to
regulate the expression of EBAF. Luciferase reporter assays showed that
the promoter activity of EBAF genewas signiﬁcantly increased by 7-fold,
which is higher than the increased folds of EBAF promoter activity by
transfection with p300, Smad2 and Cited2, respectively (Fig. 7A). We
sought to investigate, using Co-IP assays, whether there was a physical
interaction between these transcriptional regulators. In this experi-
ment, HCM cells were transfected with smad2-GFP expression vectors.
The immunoprecipitationwas conductedwith the anti-smad2 antibody
and the precipitated proteinswere assayed usingWestern blottingwith
the antibody against cited2 and p300, respectively. As can be seen in
Fig. 7B, smad2, cited2, and p300 were found to be present in the same
complex and worked together to contribute to the regulation of the
EBAF expression.
3.8. Down-regulation of EBAF caused abnormal activation of NODAL-
PITX2C pathway
Finally, we explore the down-stream events of EBAF down-
regulation that may inﬂuence the VDS genesis. Quantitative RT-PCR re-
sults showed that PITX2Cwas up-regulated in the disease tissues of VSD
patients (Fig. 8A, B and Supplemental Fig. S3B). Meanwhile, we found
that overexpression of NODAL gene upregulated PITX2C gene promoter
activity by luciferase reporter assay. However, the upregulation of
PITX2C promoter activity was attenuated when EBAF expression plas-
mid was co-transfected with NODAL expression plasmid (Fig. 8C).
These results indicated down-regulation of EBAF may partly participat-
ed in occurrence of VSD by abnormally activating the NODAL-PITX2C
pathway.
4. Discussion
Observational epidemiological studies of CHD have demonstrated
the existence of gene predispositions. However, the genetic basis of
themajority of CHD remains unknown, for most CHDs, the basic patho-
genetic mechanism of VSD is still unclear. However, to date, very few, p300, and smad2 cooperatively up-regulated EBAF promoter activity. HCM cells were
mids, and lysed for luciferase reporter assays. (B) smad2, cited2, and p300were presented
asmid were prepared and precipitated with the anti-smad2 antibody, then detected using
Fig. 8. EBAF down-regulation led to abnormal activation of NODAL-PITX2C pathway. (A) Comparison of PITX2CmRNA expression in 32 samples (16 samples with VSDs and 16 samples
without), as revealed by quantitative PCR. **p b 0.01 versus normal group. (B) Comparison of PITX2CmRNA expression between the normal controls (combined) and the different sub-
types of VSDs, respectively. M-VSD, S-VSD, A-VSD representmembranous ventricular septal defects, supracristal ventricular septal defects, and atrioventricular canal type defects, respec-
tively. **p b 0.01 versus normal group. (C) The up-regulation of PITX2C promoter activity by NODAL overexpression was attenuated when EBAF expression plasmid was co-transfected
with NODAL expression plasmid. HCM cells were transfected with EBAF reporter plasmid, together with NODAL and EBAF expression plasmids, and lysed for luciferase reporter assays.
*p b 0.05 versus transfection of vector group; **p b 0.01 versus transfection of vector group; #p b 0.05 versus transfection of NODAL expression plasmid only group. Data are from
three independent experiments. (D) A sketched diagram shows the regulatory mechanisms driven by smad2, cited2, p300, EBAF and NODAL-PITX2C pathway in heart development.
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characterization of novel genes and proteins associated with VSD re-
mains an important issue. Here, we ﬁnd that the expression of EBAF
was frequently down-regulated in VSD tissues for the ﬁrst time (Fig. 2
and Supplemental Fig. S3A). Furthermore, we also found that down-
regulation of EBAF was associated with cardiomyocyte apoptosis by
Annexin V-FITC and RT-PCR assays (Fig. 3A and B).
Then,we explored the down-streamevents of EBAF down-regulation
that may inﬂuence the VDS genesis. EBAF, a feedback inhibitor of NODAL
signaling, blocks NODAL signaling and rapidly terminates the expression
of both NODAL and its target gene such as PITX2C [18]. PITX2C up-regulation was recently reported to be associated with the occurrence
of ventricular septal defect [19]. Thus, we speculate that EBAF down-
regulation may partly lead to VSD by abnormal activation of NODAL
pathway. Luciferase reporter assay and quantitative RT-PCR results indi-
cated down-regulation of EBAF may partly participate in occurrence of
VSD by abnormally activating NODAL-PITX2C pathway (Fig. 8 and Sup-
plemental Fig. S3B). This study established the association of EBAF with
VSD genesis.
Here, we report that the expression of EBAF was frequently
down-regulated in VSD tissues for the ﬁrst time (Fig. 2A), furthermore,
we found that EBAF was frequently down-regulated in membranous
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EBAF was also down-regulated in supracristal ventricular septal defects
and atrioventricular ventricular septal defect (two other subtypes of
VSD) in our study (Fig. 2B), the results should be further conﬁrmed by
increasing the numbers of the samples. However, we were not able to
conﬁrm this now because of low incidence of the two subtypes of VSD
and so no tissues could be acquired right now. The ﬁndings of this
study indicate that decreased EBAF expression may play an important
role in the onset of different subtypes of ventricular septal defects
(Table 1, Fig. 2 and Supplemental Fig. S3A).
Low expression of EBAF and its regulatory mechanism of under-
expression in patients with VSD have been clariﬁed in this study. West-
ern blotting has indicated that cited2 expression is associated with
under-expression of EBAF (Fig. 4). Further investigation using luciferase
reporter assays and ChIP assays suggested that smad2 and cited2 did
contribute to the regulation of EBAF expression (Fig. 5). Moreover, one
signiﬁcant ﬁnding that has emerged from this study is the role that his-
tone acetylase p300 inmediating cardiac development, through acetylat-
ing the histone H4 at the promoter regions of EBAF by luciferase reporter
and ChIP assays (Fig. 6A, B and C). cited2 protein, the transactivator, has
no DNA-binding domain. p300, an acetyl transferase, has no DNA-
binding domain neither. They should be recruited by transcriptional fac-
tor to the promoter of target gene to coactivate gene transcription. Co-IP
assays showed that the interaction of smad2 with p300 and cited2
(Fig. 7), may facilitate the recruitment of p300 and cited2 to the promot-
er of EBAF gene. These data suggest that the cooperation of p300, cited2,
and smad2 plays a critical role in transcriptional regulation of EBAF in
ventricular septal conﬁrmation in the process of cardiac development.
CITED2 plays an important role in the normal development of the
heart based on previous ﬁndings from gene-targeted mice. However,
the correlation between CITED2 gene and congenital cardiacmalforma-
tion genesis needs to be further validated with human sample. A recent
study showed that CITED2 mutations were associated with congenital
heart defects genesis by using human blood samples [22]. Our study
also found in abnormal expression of CITED2 was correlative with VSD
genesis by using patients' tissues (Fig. 2). Further study showed that
CITED2 participated in EBAF gene transcriptional regulation (Fig. 3).
Thus, our ﬁndings provide another important evidence that CITED2 is
essential for congenital heart defects genesis. Moreover, we also found
the responsive gene of CITED2 in cardiac development.
To conclude, this study established the association of EBAFwith VSD
genesis with patients' tissues. Further study showed that the expression
pattern of EBAFwas potentially associated with cardiomyocyte apopto-
sis by Annexin-V and RT-PCR assays. As shown in Fig. 8D, We also
showed that down-regulation of EBAF may partly participate in the oc-
currence of VSD by abnormally activating the NODAL-PITX2C pathway.
Furthermore, our data revealed that histone acetyltransferase p300was
involved in the activation of EBAF through inducing hyperacetylation of
histone H4 at the EBAF promoter. Luciferase reporter assays and co-
immunoprecipitation revealed that EBAF is regulated by a transcription-
al complex including p300, smad2, and cited2. The sketched diagram
showed the regulatory mechanisms driven by smad2, cited2, p300,
EBAF and NODAL-PITX2C pathway in heart development. Generally
speaking, our ﬁndings reveal not only a novel regulatory mechanism
of EBAF; they also indicate that smad2, cited2, p300 and EBAF play im-
portant roles in modulating the conﬁrmation of the ventricular septal.Acknowledgments
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